A

Investing in A – An In-Depth Overview for Investors

Large-cap Industrials company Agilent Technologies has logged a -2.1% change today on a trading volume of 102,134. The average volume for the stock is 1,757,237.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. Based in Santa Clara, United States the company has 18,100 full time employees and a market cap of $37,948,678,144. Agilent Technologies currently offers its equity investors a dividend that yields 0.7% per year.

The company is now trading -5.47% away from its average analyst target price of $137.0 per share. The 16 analysts following the stock have set target prices ranging from $119.0 to $165.0, and on average give Agilent Technologies a rating of buy.

Over the last 12 months A shares have declined by -13.5%, which represents a difference of -35.0% when compared to the S&P 500. The stock's 52 week high is $155.75 per share and its 52 week low is $96.8. Based on Agilent Technologies's average net margin growth of 3.4% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2022 6,848,000 1,254,000 18 -5.26
2021 6,319,000 1,210,000 19 46.15
2020 5,339,000 719,000 13 -38.1
2019 5,163,000 1,071,000 21 250.0
2018 4,914,000 316,000 6 -60.0
2017 4,472,000 684,000 15
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS